The city of Chicago, Illinois, currently has 14 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
Recruiting
The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
A Study to Investigate Leramistat in Patients With IPF
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: GenHarp Clinical Solutions, Chicago, Illinois
Conditions: Idiopathic Pulmonary Fibrosis